HGSI, ZCNW, CIT, BLKL, BBDA, MSTF
Our Stocks to Watch tomorrow include Human Genome Sciences Inc. (Nasdaq: HGSI), Zcom Networks Inc. (OTC: ZCNW), CIT Group Inc. (NYSE: CIT), Blink Logic Inc. (OTCBB: BLKL), Bebida Beverages Co. (OTC: BBDA) and Monarch Staffing Inc. (OTC: MSTF).
HUMAN GENOME SCIENCES INCORPORATED (NASDAQ: HGSI)
"Up 276.81% on Monday"
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon® (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B®) for lupus. Albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are ongoing, with results expected in July and November 2009. In April 2009, HGS completed delivery of 20,000 doses of raxibacumab (ABthrax(TM)) to the U.S. Strategic National Stockpile for use in an emergency for the treatment of inhalation anthrax. The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria® (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes.
July 20 -
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA™ in Systemic Lupus Erythematosus
BENLYSTA (Belimumab) Met Its Primary Efficacy Endpoint by Achieving a Statistically Significant Improvement in Patient Response Rate Versus Placebo in BLISS-52; First Drug for Lupus to Reach This Advanced Stage of Clinical Development and Achieve Positive Results, in the Largest Randomized Placebo-Controlled Clinical Trial Ever Completed in SLE Patients
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA™ (belimumab, formerly LymphoStat-B) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that BENLYSTA plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
"The BLISS-52 results demonstrated that BENLYSTA has the potential to become the first new approved drug in decades for people living with systemic lupus," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Given the limited treatment options currently available, patients would benefit greatly from potential new treatments. BENLYSTA is an outstanding example of the type of treatment HGS is working to develop and bring to patients. Assuming positive results in November from our second Phase 3 trial of BENLYSTA, we and GSK plan to submit marketing applications in the United States, Europe and other regions in the first half of 2010."
Belimumab is an investigational drug and the first in a new class of drugs called BLyS-specific inhibitors. No new drug for lupus has been approved by regulatory authorities in more than 50 years. Belimumab is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.
"Lupus is a chronic, often debilitating, and sometimes fatal illness that affects an estimated five million people worldwide and can have a devastating effect on both patients living with the disease and their families," said Carlo Russo, M.D., Senior Vice President, Biopharm Development, GSK. "BENLYSTA is the first medicine being developed specifically for lupus that has reached this late stage of clinical development with positive results. We look forward to completing the pivotal studies, with the hope of bringing this potentially important therapeutic advance to patients suffering from SLE."
ZCOM NETWORKS INCORPORATED (OTC: ZCNW)
Zcom is a multi-industry company with two core businesses: Media Broadcasting/Home Shopping Division and Mineral rights/Real Estate Division. Zcom offers radio and video content delivered live and on demand over the internet. Audiences can access programs 24 hours a day, seven days a week, directly or via podcast. The company is in the process of launching a Direct Broadcast Satellite (DBS) and IP TV broadcast that will reach over 10 million households in the US, Canada and Mexico. Zcom also offers products and services through its Home Shopping Network marketed and promoted through the company's TV/IP TV broadcast resources and through its affiliate network. Existing products/services include Super Fuel and TV Box. Zcom's Mineral Rights/Real Estate Division owns a mining development, exploration and extraction company with a 160 acre gold, silver, tungsten, platinum and copper placer mining claim -- CLS #12 in Ridgecrest, California. Additionally, Zcom is a joint venture partner in the Playa Paraiso Development Project in Panama, which includes the construction and sale of 5 beachfront villas and 20 condominiums.
July 20 -
Zcom Networks Subsidiary Announces Compliance and Record Revenue and Earnings
Zcom Networks, Inc. (OTC: ZCNW) announced that Kortel Communications, Inc. (www.kortel.net), a Zcom Subsidiary, recorded annual revenue of $16,292,730 and profitable operations for 2008. In addition, Kortel, which provides a wide range of telecommunication services with extensive network infrastructure, international routes, and connectivity, has obtained its complaisance with Cisco, Quintum, Neura, and all H323 systems. This reach minimizes, or can even eliminate, the local access circuit cost which all too often becomes the highest cost item in connectivity. Kortel's domestic and international interconnection are offered via VOIP (Voice over Internet Protocol), TDM derived, E1, or traditional interfaces.
"Utilizing its extensive cost effective proprietary IP/TDM hybrid switch and network POPS globally, Kortel provides voice and data termination services with highest quality and reliability," said Dr. Alex Parsinia, CEO of Zcom. "We are looking forward to continued development by Kortel from its constantly expanding customer base."
CIT GROUP INCORPORATED (NYSE: CIT)
"Up 78.57% on Monday"
CIT Group Inc. is a bank holding company with more than $60 billion in finance and leasing assets that provides financial products and advisory services to small and middle market businesses. Operating in more than 50 countries across 30 industries, CIT provides an unparalleled combination of relationship, intellectual and financial capital to its customers worldwide. CIT maintains leadership positions in small business and middle market lending, retail finance, aerospace, equipment and rail leasing, and vendor finance. Founded in 1908 and headquartered in New York City, CIT is a member of the S&P 500 and Fortune 500.
July 20 - Bondholders Work to Save CIT Group Inc.
Reuters is reporting that CIT Group Inc. (NYSE: CIT) has negotiated a deal with bondholders that should save the company from immediate bankruptcy. For details, visit www.reuters.com/article/marketsNews/idINN1932306420090720?rpc=44.
July 17 -
Beacon Equity Issues Investment Report for CIT Group Inc.
BeaconEquity.com announces an investment report featuring commercial lender CIT Group Inc. (NYSE: CIT). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on CIT Group Inc. should be of particular interest to credit services companies: Orix Corp. (NYSE: IX), Citigroup Inc. (NYSE: C), Mizuho Financial Group Inc. (NYSE: MFG) and SunTrust Banks Inc. (NYSE: STI).
In the report, the analyst notes:
"The Company recently announced it has been advised that there is no appreciable likelihood of additional government support being provided over the near term. Previously, it confirmed that it remains in active discussions with its principal regulators on a series of measures to improve the Company's near-term liquidity position...
"Shares of CIT plummeted yesterday as consumers, analysts and investors awaited word on what the struggling commercial lender will do next to avert bankruptcy. The Company Thursday afternoon emerged from discussions with government agencies with word that the Obama administration declined to bailout the small-business financer on the grounds that it doesn't meet the standards for government aid. This would be the second bailout for the lender, which received a $2.33 billion bailout in December."
To read the entire report visit http://beaconequity.com/i/CIT.
BLINK LOGIC INCORPORATED (OTCBB: BLKL)
"Up 162.30% on Monday"
Blink Logic Inc. partners with ISVs to deliver SaaS Business Intelligence (BI) solutions to business executives in companies of all sizes. With the Blink Logic platform, ISVs can enhance their customer offerings to include powerful, yet easy-to-understand, reporting and analytics. Executives can leverage a full range of BI capabilities and actionable information to enable them to make better, faster, more informed decisions, in order to continuously increase revenue, customer satisfaction and profitability. Blink Logic is provided as a secure internet-based solution. By sharing the software, hardware, maintenance and support costs across tens of thousands of customers, Blink Logic delivers tremendous capability to its partners and their customers at a low monthly subscription price.
July 20 -
Blink Logic Participates in BeyeNETWORK's Software-as-a-Service Research Study
Research Study Focuses on the Benefits of Software as a Service (SaaS) and How Customers Are Using SaaS in a Decision-making Environment
Blink Logic Inc. (OTCBB: BLKL), the innovation leader in Software as a Service (SaaS) Business Intelligence (BI) announced its participation in the recent research study, Pay as You Go: Software as a Service Business Intelligence and Data Management. This study was published by BeyeResearch™, a community resource produced by the Business Intelligence Network.
The study, conducted by Claudia Imhoff of Intelligent Solutions and Colin White of BI Research, focuses on the benefits of software as a service (SaaS) and how this applies to business intelligence. With SaaS gaining more and more attention, there is still some confusion around SaaS and if a BI solution can thrive in a SaaS environment. The study also includes case studies highlighting real customer experiences and “lessons learned” when implementing a SaaS solution.
“In these tough economic times, it’s more important than ever for decision makers to have the information they need, when they need it and to immediately be able to slice and dice that data,” says David Morris, CEO of Blink Logic. “Companies can’t afford to spend the months it would take to install a system in house or the years it would take to build it themselves. SaaS BI is extremely cost effective and has a very low risk.”
BEBIDA BEVERAGE COMPANY (OTC: BBDA)
"Up 50.00% on Monday"
The company, formerly known as Fortis Enterprises, was founded in 2000 and is based in Casselberry, Florida. On Sept. 4, 2008, Renovo Holdings announced that the company had changed its name to Bebida Beverage Company and would be locating the base of the company's North American presence in Las Vegas, NV. Bebida Beverage Company hopes to concentrate operations on the bottled water and enhanced beverage markets of North and South America. Bebida's management will focus the company's business efforts within the United States and key target markets within Latin America.
July 20 -
Bebida's Driver 'Thrillin' Dillon to 'Chillin' Dillon After Hard Kentucky Wreck
Potencia USA LLC's Potencia Energy Drink, in alliance with Bebida Beverages Company (OTC: BBDA), enjoyed a great week with the continued expansion of distribution.
However the NASCAR Camping World Truck Series team the partnership sponsors did not fare as well at the Kentucky Speedway for the BUILT FORD TOUGH 225. Thrillin Dillon Oliver in his 3rd NASCAR Truck Series start backed by Piranha Water & Potencia Energy Drink had steadily climbed up the speed charts during Friday's practice session driving the #02 Corrie Stott Racing Chevrolet Silverado.
When the last practice came to a close Dillon's speed was well in the top 24 despite using tires on his ride with many laps on them. Bolting on 4 new racing Goodyear Wrangler tires insured added speed.
The team pushed the Chevy to the qualify line on Saturday with excitement and dedication to a young star to be, who was coming off his career best finish two weeks prior at Rockingham Speedway with the ASA Late Model Series. Dillon climbed aboard the Chevy and took off for his time around the high speed mile and half track. Entering turn one at an excess of 175 miles per hour the Chevy stuck to the track until the center of the corner, where the added speed from fresh tires caused a bottoming out effect. Oliver slammed hard into the retaining wall first with the front and then the rear of the #02 Chevy. The wreck was rather severe as the whole truck is in essence destroyed beyond repair. Oliver was rushed to the infield care center where he was alert and doing ok. Later x-rays proved a bone to be broken in his right foot.
"It's an unfortunate result for our brands, but nothing in this world is worth the health and safety of our driver. We are dedicated to him and his racing journey and we are dedicated to continue to use all types of auto racing as marketing and branding tools," said CEO Brian Weber.
"Dillon came by our office this morning and asked for some Koma Unwind to calm him down as he is always on the go. So it's official: the first full bottle of Koma Unwind Relaxation Beverage from our samples is being consumed by none other than NASCAR driver Dillon Oliver," added Weber.
MONARCH STAFFING INCORPORATED (OTC: MSTF)
"Up 100.00% on Monday"
Monarch Staffing, Inc., through its subsidiaries, provides healthcare staffing services to commercial and government sector customers in the United States. It furnishes personnel to perform a range of pharmacy technician, nursing, and other health care services in support of the operations of government and commercial facilities. The company is based in Irvin, California.
July 20 -
Monarch Staffing, Inc. Awarded New Contract With the California Department of Corrections and Rehabilitation; Continues to Expand Service Offerings
Monarch Staffing, Inc. (OTC: MSTF), and its wholly owned subsidiary Drug Consultants, Inc. ("DCI"), a provider of healthcare staffing services, announced the award of a new contract with the California Department of Corrections and Rehabilitation ("CDCR").
The contract is for Occupational Therapy Services at the CDCR and expires June 30, 2010.
"We are extremely pleased with the bid and award process with the CDCR. Our new Occupational Therapy Services Contract coupled with other recent contract awards will allow us to continue to diversify our staffing services provided to the State of California and continue to facilitate the growth the Company is experiencing," commented David Walters, Chairman.
DCI furnishes personnel to perform a range of pharmacy, nursing and other healthcare staffing services in support of the operations of government and commercial facilities, including its largest client, the California Department of Corrections and Rehabilitation. DCI has experience in providing its services in rural areas of California where many state facilities are located and healthcare professionals are not readily available.